



Corporate Press Release

28th April 2011

MOVIPREP[®] is launched in Canada

Norgine and Medical Futures are pleased to announce the launch of MOVIPREP, a bowel cleansing preparation, in Canada.

"The launch of MOVIPREP underlines Medical Futures' commitment to the prevention and treatment of gastrointestinal diseases," said Colin Campbell, Medical Futures' CEO.

Commenting on the launch Peter Stein, Norgine's CEO, said: "We are delighted that our collaboration with Medical Futures has reached this important milestone. We have been impressed by Medical Futures' commitment to bringing MOVIPREP to Canada, by their in-depth knowledge of the Canadian regulatory requirements and by their strong presence in the Canadian gastroenterology market."

MOVIPREP is marketed by Norgine in Europe, in the USA by its partner Salix Pharmaceuticals and is under development in Japan by Ajinomoto and in Central and Eastern Europe by PharmaSwiss.

ENDS

About Norgine

Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2009, Norgine's net product sales were €253 million, the 23rd year of double-digit growth at constant exchange rates. The Company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a bowel cleansing preparation, KLEAN-PREP[®] for bowel preparation prior to colonoscopy, XIFAXAN[®] for the treatment of travellers diarrhoea and hepatic encephalopathy and ORAMORPH[®] for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France.

Norgine Contact

Julie Hornby Winfield
Global Corporate Communications Manager
+44 (0) 1895 826600
jhornbywinfield@norgine.com

About Medical Futures

Medical Futures Inc. is a niche pharmaceutical company that distributes both pharmaceutical and natural therapeutic products into the North American marketplace. Founded in 2000, this privately held company is dedicated to advancing the quality of life of all North Americans. The current product offering includes:

Florastor® and FlorastorKids®: The number one probiotic worldwide in terms of clinical evidence, efficacy, sales and distribution. Florastor helps provide effective relief of diarrhoea across multiple indications including antibiotic associated and acute infections for both adults and children.

Iberogast®: Used for over 45 Years in Europe with over 40 clinical trials for gastrointestinal conditions such as irritable bowel syndrome and dyspepsia. Iberogast provides proven relief of heartburn, bloating, cramping nausea and abdominal pain.

Proferrin™: Canada's only heme based iron supplement. Heme iron has high absorption and low side effects.

Pegalax™: Clinically proven relief of occasional constipation with an impressive safety profile and effective worldwide use for more than 10 years.

Mutaflor®: A unique and powerful probiotic providing relief from constipation and diarrhoea. Studied in Europe for over 80 years with clinical trials showing improvement in gastrointestinal symptoms associated with conditions such as ulcerative colitis, Crohn's disease and irritable bowel syndrome.

Purfem™ Probiotic: A novel probiotic containing *Lactobacillus* in a vaginal ovule that renews intimate freshness and comfort.

For more information about Medical Futures Inc. please see www.medfutures.com

Medical Futures Inc. Contact

Matthew Kostanecki
Product Manager
Tel: +1 905 731 0294
matthew@medfutures.com